Antiangiogenic therapy shows promise as a treatment strategy for highly vascularized tumors such as GBM. Sunitinib is a multitargeted kinase inhibitor that selectively inhibits various RTKs, including those playing key roles in angiogenesis, such as VEGFRs and PDGFRs.Sutent is currently in a phase II study: SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme (SURGE01-07), NCT00535379 .
The objective of this study is to determine the efficacy and safety of SUTENT in patients with recurrent or progressive glioblastoma multiforme. Patients with tissue based diagnosis of intracranial glioblastoma multiforme, above 18 years of age and of both genders, who have a first tumor recurrence or progress after surgery, radiation- and chemotherapy will be included. The hypothesis is that SUTENT will significantly increase the progression free survival rate at 6 months in the study population.